Amid market volatility driven by AI speculation, a seasoned investor makes the case for a dual-anchor strategy built on Apple's surging iPhone sales and Berkshire Hathaway's formidable $378 billion cash reserve.
Under new CEO Michael Leiters, Porsche is reportedly considering axing its planned all-electric 718 Boxster and Cayman line. The potential move, driven by development hurdles and soaring costs, signals a strategic recalibration as the automaker grapples with a sales slowdown in China and the financial weight of revising its EV roadmap.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
The Ermenegildo Zegna Group reported a 1.1% organic revenue increase to €1.91 billion for 2025, powered by robust DTC performance. While annual sales dipped slightly on a reported basis, a strong fourth-quarter acceleration signals the payoff of its strategic channel shift.
VEON is deepening its investment in Uzbekistan's digital economy with a new network operations center for Beeline and the launch of BuildX, a software and AI development unit. The moves signal a strategic pivot from traditional telecom services towards higher-margin digital offerings in Central Asia.
The spirits giant files for legal protection for its production and warehouse assets in Latvia, citing cash flow pressures from geopolitical fallout and market headwinds, while assuring global sales remain unaffected.
Despite underperforming the broader market since August 2025, insurance marketplace platform MediaAlpha (MAX) exhibits robust fundamentals—including sustained sales growth, expanding cash flow margins, and rising returns on capital—that could signal significant upside potential for patient investors.
While many chase high-risk, loss-making stories, Tyler Technologies (TYL) stands out with consistent profitability and growth. We examine the key metrics and management alignment that make this software provider a stock worth watching.
Mazda Motor Corporation's global vehicle production saw a significant rebound in December 2025, offering a positive end to a year where overall output and sales declined. The recovery was driven by strong domestic performance and a mixed picture overseas.
Graco Inc. delivered solid fourth-quarter results, meeting analyst forecasts with 8% sales growth driven by acquisitions and stable core demand. While management expressed confidence in integration efforts and margin initiatives, analysts on the earnings call pressed for details on long-term profitability and market headwinds.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.
While the UK kitchenware retailer maintains sales growth, a five-year decline in a key profitability metric and rising liabilities signal potential headwinds for investors.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
